# A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

> **NCT05102370** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Clonal Cytopenia of Undetermined Significance
- CCUS Clonal Cytopenia of Undetermined Significance

## Interventions

- **DRUG:** Enasidenib

## Key facts

- **NCT ID:** NCT05102370
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-06
- **Primary completion:** 2026-01-26
- **Final completion:** 2026-01-26
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05102370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05102370, "A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05102370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*